
Pre-congress Industry Workshop 2
In Vivo CAR-T: The Next Standard of Care for Autoimmune Disease? Synopsis: In vivo CAR-T therapy is emerging as a transformative treatment approach for B cell–mediated autoimmune disease, such as systemic lupus erythematosus, systemic scleroderma, and idiopathic inflammatory myopathies, delivering the deep immune reset associated with cell therapy without the complexity and cost of ex vivo manufacturing. As momentum in the field accelerates, CREATE Medicines is bringing together international leaders in cell therapy and rheumatology to explore a thought-provoking question:





